Skip to content
Subscriber Only

Former Shire CEO Shakes Up Galderma as IPO Decision Looms

  • Ornskov seeks to double down on science at skincare business
  • Former Nestle unit boosts R&D spending and adds dermatologists
Flemming Ornskov
Flemming OrnskovPhotographer: Jason Alden/Bloomberg

Flemming Ornskov led Shire’s expansion into rare diseases before the drugmaker’s $62 billion sale to Takeda Pharmaceutical Co. in 2019. Now he’s plotting a new course for a skincare business that Nestle SA gave up on.

Ornskov, who took the reins of Switzerland-based Galderma two years ago, said in an interview that he’s “doubling down on science,” accelerating research spending and adding dermatologists and medical specialists as the company prepares for a potential initial public offering.